Rein Therapeutics (RNTX) Intangibles (2023 - 2026)
Rein Therapeutics (RNTX) posted quarterly Intangibles of $13.5 million for Q1 2026, down 68.01% year-over-year from $42.2 million in Q1 2025, and little changed quarter-over-quarter from $13.5 million in Q4 2025.
Rein Therapeutics (RNTX) Intangibles (2023 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Intangibles for 4 consecutive years, with $13.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 68.01% year-over-year to $13.5 million; the TTM figure through Mar 2026 stood at $13.5 million (down 68.01% YoY), while the FY2025 annual figure was $13.5 million, down 68.01% from the prior year.
- Intangibles was little changed at $13.5 million in Q1 2026 per RNTX's latest filing, from $13.5 million in the prior quarter.
- Across five years, Intangibles topped out at $79.2 million in Q4 2023 and bottomed at $13.5 million in Q4 2025.
- Historically, Intangibles has averaged $51.3 million across 4 years, with a median of $42.2 million in 2024.
- Annual changes were most pronounced in 2024 — Intangibles sank 46.72% — and 2025, when it slumped 68.01%.
- Rein Therapeutics' Intangibles stood at $79.2 million in 2023, then tumbled by 46.72% to $42.2 million in 2024, then slumped by 68.01% to $13.5 million in 2025, then changed by 0.0% to $13.5 million in 2026.
- Business Quant data shows RNTX's Intangibles at $13.5 million in Q1 2026, $13.5 million in Q4 2025, and $42.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 13.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.50 Mn |
| Mar 31, 2026 | 13.50 Mn |
| Dec 31, 2025 | 13.50 Mn |
| Sep 30, 2025 | 42.20 Mn |
| Jun 30, 2025 | 42.20 Mn |
| Mar 31, 2025 | 42.20 Mn |
| Dec 31, 2024 | 42.20 Mn |
| Sep 30, 2024 | 79.20 Mn |
| Jun 30, 2024 | 79.20 Mn |
| Mar 31, 2024 | 79.20 Mn |
| Dec 31, 2023 | 79.20 Mn |